Strategies for Improving Drug Safety in Europe: Can General Practitioners Contribute ?

1991 ◽  
pp. 3-6
Author(s):  
Andrew Herxheimer
Keyword(s):  
General Practitioners ◽  
Drug Safety

Polypharmazie – Lösungswege für eine verbesserte Arzneimitteltherapiesicherheit

2017 ◽  
Vol 142 (14) ◽  
pp. 1046-1053
Author(s):  
Olaf Krause ◽  
Gesine Picksak ◽  
Ulrike Junius-Walker
Keyword(s):  
Older People ◽  
General Practitioners ◽  
Nursing Care ◽  
Drug Safety ◽  
Medication Management ◽  
Team Work ◽  
Communication Tool ◽  
Old People ◽  
Medication Plan ◽  
Drug Problems

AbstractPolypharmacy (≥ 5 drugs) is common among older people and may lead to falls, ADEs and delirium. Adherence is an important part in the medication management. Simple questions (i. e. for OTC, handling and omission of drugs) are effective. As most old people are treated by general practitioners (GP), they play a key role for drug safety and reducing polypharmacy. The involvement of pharmacists in analyzing one patient‘s drugs can enhance solutions for drug problems (“two-man rule”). An IT-based medication plan acts as an important communication tool for an enhanced team work between doctors, pharmacists and nursing care.

General practitioners and postmarketing surveillance

1984 ◽  
Vol 22 (21) ◽  
pp. 83-84
Keyword(s):  
Adverse Effects ◽  
General Practitioners ◽  
Drug Safety ◽  
Clinical Studies ◽  
New Drugs ◽  
Postmarketing Surveillance ◽  
Number Of Patients ◽  
Main Effects

Many new drugs or new formulations will have been given to less than two thousand patients at the time a licence is issued. Clinical studies carried out before marketing will have demonstrated the drug’s main effects and its apparent safety. Adverse effects may only be recognised much later when a large number of patients have been treated. This was the case with benoxaprofen, Osmosin, zimeldine and zomepirac. The speedy recognition of such problems requires the help of all prescribers, but particularly of GPs who are especially likely to prescribe newly promoted drugs. Government has promised funds to help improve the collection and dissemination of information about drug safety.1

36: Management of Patients with Elevated Prostate Specific Antigen Level among General Practitioners in Switzerland

2005 ◽  
Vol 173 (4S) ◽  
pp. 10-11
Author(s):  
Markus Fatzer ◽  
Michael Muentener ◽  
Raeto T. Strebel ◽  
Dieter Hauri ◽  
Hubert A. John
Keyword(s):  
Prostate Specific Antigen ◽  
General Practitioners ◽  
Specific Antigen ◽  
Prostate Specific Antigen Level ◽  
Antigen Level

FDA's New Drug Safety Board Under Scrutiny

2005 ◽  
Vol 39 (3) ◽  
pp. 51
Author(s):  
JENNIFER SILVERMAN
Keyword(s):  
Drug Safety ◽  
New Drug

FDA Plans to Strengthen Drug Safety Program

2005 ◽  
Vol 36 (1) ◽  
pp. 43
Author(s):  
ELIZABETH MECHCATIE
Keyword(s):  
Drug Safety ◽  
Safety Program

Lymphedema and lipedema - an overview of conservative treatment

VASA ◽  
2011 ◽  
Vol 40 (4) ◽  
pp. 271-279 ◽  
Author(s):  
Wagner
Keyword(s):  
Conservative Treatment ◽  
General Practitioners ◽  
Subcutaneous Tissue ◽  
Compression Therapy ◽  
Compression Stocking ◽  
Lymph Drainage ◽  
Intensive Phase ◽  
Manual Lymph Drainage ◽  
Causal Therapy

Lymphedema and lipedema are chronic progressive disorders for which no causal therapy exists so far. Many general practitioners will rarely see these disorders with the consequence that diagnosis is often delayed. The pathophysiological basis is edematization of the tissues. Lymphedema involves an impairment of lymph drainage with resultant fluid build-up. Lipedema arises from an orthostatic predisposition to edema in pathologically increased subcutaneous tissue. Treatment includes complex physical decongestion by manual lymph drainage and absolutely uncompromising compression therapy whether it is by bandage in the intensive phase to reduce edema or with a flat knit compression stocking to maintain volume.

Sign in / Sign up

Export Citation Format

Share Document